Dianthus Therapeutics Welcomes Dr. Simon Read to Its Board

Author: Evelyn Baker Updated: 05-22-2025 04:15 PM

Dr. Simon Read Joins Dianthus Therapeutics Board

Dr. Simon Read has been appointed to the Board of Directors of Dianthus Therapeutics, Inc. This decision comes as the company continues to pave the way in developing antibody complement therapeutics aimed at treating severe autoimmune diseases.

Expertise in Biopharmaceuticals

With over 30 years in the biopharmaceutical industry, Dr. Read brings a wealth of knowledge and leadership experience. He is known for his success as the CEO and Founder of Mariana Oncology and served as the Chief Scientific Officer at Ra Pharma. His leadership has driven significant advancements and innovations in drug development.

Transition on the Board

Alongside Dr. Read's exciting appointment, Lonnie Moulder will be stepping away from his role on the Board of Directors. Alison Lawton, Chair of Dianthus, expressed her gratitude for Moulder's contributions, citing his vital support during the company's rapid growth from a private to a publicly traded entity.

Recognizing Contributions and Looking Ahead

Lonnie Moulder highlighted the impressive progress Dianthus has made, particularly in advancing its complement inhibitors since initial investments started in 2019. His optimism for Dianthus' future underscores a strong foundation that supports ongoing clinical trials.

Dr. Read's Background

Before joining Dianthus, Dr. Read's career featured significant roles at GlaxoSmithKline, AstraZeneca, and Roche/Genentech. He was instrumental in the clinical development of prominent immunology drugs, which contributes to his expertise today.

Commitment to Innovation

In his new position, Dr. Read expressed enthusiasm about collaborating with the Dianthus team, especially concerning the forthcoming Phase 2 MaGic trial results expected soon. He believes DNTH103 holds the potential to become a groundbreaking therapy for patients with severe neuromuscular disorders.

About Dianthus Therapeutics

Dianthus Therapeutics stands at the forefront of biopharmaceutical innovation, focusing on the design and delivery of cutting-edge monoclonal antibodies. The company operates from its bases in New York City and Waltham, aiming to create transformative therapies for patients battling severe autoimmune and inflammatory diseases.

Company Vision and Future Goals

With a dedicated team of industry veterans, Dianthus continues to make strides in research and development, bolstered by a commitment to creating therapies that significantly improve patient outcomes.

Contact Information

For further inquiries, please reach out to:

Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

Frequently Asked Questions

Who is Dr. Simon Read?

Dr. Simon Read is a biopharmaceutical expert with over 30 years of experience and has been appointed to Dianthus Therapeutics' Board of Directors.

What role did Lonnie Moulder play at Dianthus?

Lonnie Moulder served on the Board of Directors and played a crucial role in guiding Dianthus' growth from a private entity to a public company.

What is DNTH103?

DNTH103 is a potential therapeutic designed by Dianthus Therapeutics aimed at treating severe neuromuscular conditions, currently in Phase 2 trials.

What is the focus of Dianthus Therapeutics?

Dianthus focuses on developing advanced antibody therapies to address severe autoimmune and inflammatory diseases.

How can I learn more about Dianthus Therapeutics?

You can visit their official website at www.dianthustx.com.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.